Shock wave therapy: ED cure or unproven treatment? - Urology …
WEBAug 6, 2019 — Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important unanswered questions, including which patients are ideal candidates and which protocol and devices are best. Without answers, offering the ED treatment ...
New recurrent UTI guideline: What urologists need to know
WEBOct 7, 2019 — The index patient is an otherwise healthy adult female with an uncomplicated, culture-proven recurrent UTI associated with acute-onset symptoms. Central to a diagnosis of UTI is the symptom of dysuria. Dysuria is a highly specific symptom, with more than 90% accuracy for UTI in young women in the absence of concomitant vaginal irritation or ...
Long-term results of Rezum therapy for patients with large prostates
WEBDec 23, 2021 — So, the retreatment rate for our small prostate cohort was 4.4%, which is in line with the results demonstrated from the original WATER clinical trial, 3 which also had a retreatment rate of 4.4%. For our large prostate cohort, this subset of patients had a retreatment rate of 18.4%, so a little less than one in five patients required ...
Dr. Elterman discusses Rezum and Aquablation for patients with BPH
WEBSep 10, 2021 — Dean Elterman, MD. At the 2021 American Urological Association annual meeting, Dean Elterman, MD, MSc, FRCSC, presented the studies “Rezūm water vapor therapy for large volume (≥80 mL) benign prostatic enlargement: large, multi-center cohort,” 1 and “Pooled analysis of bladder function post-Aquablation.” 2.
Advancements in Minimally Invasive Surgical Options for the …
WEBMar 31, 2022 — Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate affecting more than 40 million men in the United States with an associated prevalence that increases from 40% to 80% among men 50 to 70 years of age, respectively. 1,2 Progression of BPH leads to the subsequent development of lower urinary tract symptoms (LUTS), which most commonly include frequent urination ...
5-year Rezum study results show low rates of erectile and …
WEBSep 23, 2021 — 5-year Rezum study results show low rates of erectile and ejaculatory dysfunction. In a recent study presented at the 2021 AUA Annual Meeting, Kevin T. McVary, MD, FACS, and co-authors assessed the 5-year outcomes of Rezum water vapor thermal therapy in patients with BPH, specifically focusing on erectile and ejaculatory function.
How testosterone therapy use in men with prostate cancer has …
WEBJan 5, 2023 — According to Khera, the need for testosterone might be greater among prostate cancer patients. “Specifically for men with a history of prostate cancer, testosterone therapy can improve recovery of erectile function following…treatment. Testosterone plays a key role in overall erectile function.”. Although every case is different ...
Aquablation safety and efficacy in BPH sustained at 5-year follow-up
WEBJul 12, 2023 — Aquablation safety and efficacy in BPH sustained at 5-year follow-up. Data showed a decrease in patient symptoms following Aquablation procedures, with an average IPSS of 22.6 at baseline compared with 6.8 at 5-year follow-up. The WATER II trial (NCT03123250) assessing Aquablation therapy for lower urinary tract symptoms (LUTS) due to benign ...
Next-generation sequencing: A reliable tool for the diagnosis and ...
WEBApr 18, 2022 — Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Impact of raising testosterone levels in men after radical …
WEBOct 21, 2021 — A “testosterone challenge” approach appears to allow for early detection of prostate cancer recurrence in men with low testosterone after radical prostatectomy (RP), according to a study presented at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. 1 The investigators found that 5 of 22 men who underwent the challenge had a rise in prostate-specific antigen (PSA ...